AOPEP

Across TCGA pan-cancer cohorts, AOPEP Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated AOPEP data layer compared with 23 for mass-spec protein.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher AOPEP Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated AOPEP expression acts as an unfavorable survival marker.

UCS, STAD, and LUAD are the cancer types where AOPEP Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	OS	Median	All	0.102	0.688	<.001	36	view →
STAD	OS	Median	II,III,IV	0.183	0.677	.004	24	view →
LUAD	OS	Median	II,III,IV	0.293	0.595	.023	9	view →
CESC	OS	Median	III,IV	0.232	0.668	.049	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LIHC	DFS	Median	II,III,IV	0.044	0.427	<.001	6	view →
SKCM	DFS	Median	II,III,IV	0.134	0.708	.013	3	view →
BRCA	OS	Median	All	0.805	0.924	.022	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

AOPEP–UCS (OS)

Open the UCS breakdown →